STOCK TITAN

[Form 4] General Mills, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) – Form 4 insider filing for CFO Alexis DeSieno

The filing discloses routine equity activity related to previously granted restricted stock units (RSUs). On 1 July 2025, 14,349 RSUs vested and were converted into an equal number of common shares (transaction code “M”). Immediately after vesting, the CFO beneficially owned 179,182 common shares.

On 2 July 2025, the CFO executed a sale of 7,324 shares (transaction code “S”) at a weighted-average price of $1.7826 to cover tax-withholding obligations associated with the RSU delivery. Post-sale, direct ownership stands at 171,858 common shares.

The RSU award originally covered 114,796 shares and vests in eight equal quarterly instalments from 1 July 2024 through 1 April 2026, conditional on continued employment. Following the reported transactions, 43,049 RSUs remain outstanding and unexercised.

  • No open-market purchase or discretionary sale occurred beyond the withholding-related disposition.
  • The transactions do not change the CFO’s executive status; they are standard Section 16 reporting items.

Implications for investors: The activity appears administrative and tax-related, signalling neither bullish nor bearish intent. Nevertheless, it provides updated visibility into insider holdings and confirms continued service of the CFO, whose remaining share and RSU position maintains alignment with shareholder interests.

Cardlytics, Inc. (CDLX) – Comunicazione interna Form 4 per la CFO Alexis DeSieno

La comunicazione riporta un'attività azionaria ordinaria relativa a unità azionarie vincolate (RSU) precedentemente assegnate. Il 1 luglio 2025, 14.349 RSU sono maturate e convertite in un pari numero di azioni ordinarie (codice transazione “M”). Subito dopo la maturazione, la CFO deteneva beneficiariamente 179.182 azioni ordinarie.

Il 2 luglio 2025, la CFO ha effettuato una vendita di 7.324 azioni (codice transazione “S”) al prezzo medio ponderato di 1,7826 $ per coprire le imposte dovute sulle RSU ricevute. Dopo la vendita, la proprietà diretta ammonta a 171.858 azioni ordinarie.

Il premio RSU originariamente comprendeva 114.796 azioni e si matura in otto rate trimestrali uguali dal 1 luglio 2024 al 1 aprile 2026, subordinatamente alla permanenza in servizio. Dopo le transazioni riportate, rimangono 43.049 RSU non esercitate e non maturate.

  • Non si sono verificati acquisti sul mercato aperto o vendite discrezionali oltre la disposizione per ritenuta fiscale.
  • Le transazioni non modificano lo status esecutivo della CFO; sono operazioni standard ai fini della Sezione 16.

Implicazioni per gli investitori: L'attività appare di natura amministrativa e fiscale, senza indicazioni rialziste o ribassiste. Tuttavia, fornisce aggiornamenti sulla detenzione interna e conferma il proseguimento del servizio della CFO, la cui posizione azionaria e RSU resta allineata agli interessi degli azionisti.

Cardlytics, Inc. (CDLX) – Presentación Formulario 4 de insider para la CFO Alexis DeSieno

La presentación revela una actividad rutinaria con acciones relacionada con unidades de acciones restringidas (RSU) previamente otorgadas. El 1 de julio de 2025, 14,349 RSU se consolidaron y se convirtieron en un número igual de acciones comunes (código de transacción “M”). Inmediatamente después de la consolidación, la CFO poseía beneficiosamente 179,182 acciones comunes.

El 2 de julio de 2025, la CFO realizó una venta de 7,324 acciones (código de transacción “S”) a un precio promedio ponderado de $1.7826 para cubrir obligaciones fiscales asociadas con la entrega de las RSU. Tras la venta, la propiedad directa es de 171,858 acciones comunes.

El premio RSU originalmente cubría 114,796 acciones y se consolida en ocho cuotas trimestrales iguales desde el 1 de julio de 2024 hasta el 1 de abril de 2026, condicionado a la continuidad laboral. Tras las transacciones reportadas, quedan 43,049 RSU pendientes y no ejercidas.

  • No hubo compras en mercado abierto ni ventas discrecionales más allá de la disposición por retención fiscal.
  • Las transacciones no alteran el estatus ejecutivo de la CFO; son operaciones estándar según la Sección 16.

Implicaciones para inversores: La actividad parece administrativa y relacionada con impuestos, sin señales alcistas ni bajistas. Sin embargo, ofrece visibilidad actualizada sobre las participaciones internas y confirma la continuidad en el cargo de la CFO, cuya posición restante en acciones y RSU sigue alineada con los intereses de los accionistas.

Cardlytics, Inc. (CDLX) – CFO Alexis DeSieno의 내부자 보고서 Form 4 제출

이 보고서는 이전에 부여된 제한 주식 단위(RSU)에 관련된 일상적인 주식 활동을 공개합니다. 2025년 7월 1일에 14,349 RSU가 성숙되어 동일한 수의 보통주로 전환되었습니다(거래 코드 “M”). 성숙 직후 CFO는 179,182 주의 보통주를 실질적으로 보유하고 있었습니다.

2025년 7월 2일, CFO는 RSU 지급과 관련된 세금 원천징수 의무를 충당하기 위해 7,324주를 판매하였으며(거래 코드 “S”), 가중평균 가격은 $1.7826였습니다. 판매 후 직접 보유 주식은 171,858주입니다.

RSU 수여는 원래 114,796주에 해당하며 2024년 7월 1일부터 2026년 4월 1일까지 8개의 동일한 분기별 할부로 성숙되며, 계속 고용 조건에 따릅니다. 보고된 거래 이후 43,049 RSU가 아직 미성숙 및 미행사 상태입니다.

  • 원천징수 관련 처분 외에 공개 시장에서의 매수나 임의 매도는 없었습니다.
  • 이 거래들은 CFO의 임원 지위를 변경하지 않으며, 표준 섹션 16 보고 사항입니다.

투자자에 대한 시사점: 이번 활동은 행정적이고 세금 관련된 것으로 보이며, 강세나 약세 의도를 나타내지 않습니다. 다만 내부자 보유 현황을 업데이트하고 CFO의 계속 근무를 확인하며, 남은 주식 및 RSU 보유가 주주 이익과의 정렬을 유지함을 보여줍니다.

Cardlytics, Inc. (CDLX) – Déclaration Formulaire 4 d’initié pour la CFO Alexis DeSieno

La déclaration révèle une activité courante liée à des unités d’actions restreintes (RSU) précédemment attribuées. Le 1er juillet 2025, 14 349 RSU ont été acquises et converties en un nombre égal d’actions ordinaires (code transaction « M »). Immédiatement après l’acquisition, la CFO détenait bénévolement 179 182 actions ordinaires.

Le 2 juillet 2025, la CFO a procédé à une vente de 7 324 actions (code transaction « S ») à un prix moyen pondéré de 1,7826 $ pour couvrir les obligations fiscales liées à la remise des RSU. Après la vente, la détention directe s’élève à 171 858 actions ordinaires.

La dotation initiale en RSU couvrait 114 796 actions et s’acquiert en huit versements trimestriels égaux du 1er juillet 2024 au 1er avril 2026, sous condition de maintien en emploi. Après les transactions rapportées, 43 049 RSU restent en suspens et non exercées.

  • Aucun achat en marché ouvert ni vente discrétionnaire n’a eu lieu en dehors de la disposition liée à la retenue fiscale.
  • Ces transactions ne modifient pas le statut exécutif de la CFO ; ce sont des opérations standard au titre de la Section 16.

Implications pour les investisseurs : L’activité semble administrative et liée à la fiscalité, sans intention haussière ni baissière. Néanmoins, elle offre une visibilité actualisée sur les participations des initiés et confirme la poursuite du mandat de la CFO, dont la position en actions et RSU reste alignée avec les intérêts des actionnaires.

Cardlytics, Inc. (CDLX) – Form 4 Insider-Meldung für CFO Alexis DeSieno

Die Meldung offenbart routinemäßige Aktienaktivitäten im Zusammenhang mit zuvor gewährten Restricted Stock Units (RSUs). Am 1. Juli 2025 sind 14.349 RSUs fällig geworden und wurden in die gleiche Anzahl Stammaktien umgewandelt (Transaktionscode „M“). Unmittelbar nach der Fälligkeit besaß die CFO 179.182 Stammaktien wirtschaftlich.

Am 2. Juli 2025 veräußerte die CFO 7.324 Aktien (Transaktionscode „S“) zu einem gewichteten Durchschnittspreis von 1,7826 $, um Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Auszahlung zu erfüllen. Nach dem Verkauf beträgt das direkte Eigentum 171.858 Stammaktien.

Die RSU-Zuteilung umfasste ursprünglich 114.796 Aktien und wird in acht gleichen vierteljährlichen Raten vom 1. Juli 2024 bis zum 1. April 2026 fällig, vorbehaltlich einer fortgesetzten Anstellung. Nach den gemeldeten Transaktionen sind noch 43.049 RSUs ausstehend und nicht ausgeübt.

  • Es gab keine Käufe am offenen Markt oder diskretionäre Verkäufe über die zweckgebundene Veräußerung hinaus.
  • Die Transaktionen ändern den Status der CFO nicht; es handelt sich um Standardmeldungen gemäß Abschnitt 16.

Implikationen für Investoren: Die Aktivität erscheint administrativ und steuerlich bedingt und signalisiert weder eine bullische noch eine bärische Absicht. Dennoch bietet sie aktualisierte Einblicke in Insider-Beteiligungen und bestätigt die fortgesetzte Tätigkeit der CFO, deren verbleibende Aktien- und RSU-Position im Einklang mit den Interessen der Aktionäre steht.

Positive
  • CFO retains a sizable ownership stake of 171,858 shares plus 43,049 unvested RSUs, reinforcing management–shareholder alignment.
  • RSU vesting confirms continued employment of the CFO through at least the next vesting dates, supporting leadership stability.
Negative
  • Insider sale of 7,324 shares, even if tax-related, can be perceived negatively by some investors.
  • Low sale price of $1.78 highlights the stock’s currently depressed valuation, which may concern shareholders.

Insights

TL;DR: Routine RSU vesting; small tax sale; neutral insider signal.

The Form 4 reflects a scheduled RSU vesting under a multi-year grant. The CFO converted 14,349 units and sold roughly half that amount strictly for tax withholding, leaving a net increase of ~7,000 shares and a total direct holding of 171,858 shares plus 43,049 unvested RSUs. Sales linked to withholding are generally viewed as administrative and carry minimal informational value compared with discretionary sales. Given the modest dollar value (~$13k) and the stated purpose, I classify the filing as neutral for valuation or sentiment. The continued large residual stake suggests ongoing alignment with shareholders.

Cardlytics, Inc. (CDLX) – Comunicazione interna Form 4 per la CFO Alexis DeSieno

La comunicazione riporta un'attività azionaria ordinaria relativa a unità azionarie vincolate (RSU) precedentemente assegnate. Il 1 luglio 2025, 14.349 RSU sono maturate e convertite in un pari numero di azioni ordinarie (codice transazione “M”). Subito dopo la maturazione, la CFO deteneva beneficiariamente 179.182 azioni ordinarie.

Il 2 luglio 2025, la CFO ha effettuato una vendita di 7.324 azioni (codice transazione “S”) al prezzo medio ponderato di 1,7826 $ per coprire le imposte dovute sulle RSU ricevute. Dopo la vendita, la proprietà diretta ammonta a 171.858 azioni ordinarie.

Il premio RSU originariamente comprendeva 114.796 azioni e si matura in otto rate trimestrali uguali dal 1 luglio 2024 al 1 aprile 2026, subordinatamente alla permanenza in servizio. Dopo le transazioni riportate, rimangono 43.049 RSU non esercitate e non maturate.

  • Non si sono verificati acquisti sul mercato aperto o vendite discrezionali oltre la disposizione per ritenuta fiscale.
  • Le transazioni non modificano lo status esecutivo della CFO; sono operazioni standard ai fini della Sezione 16.

Implicazioni per gli investitori: L'attività appare di natura amministrativa e fiscale, senza indicazioni rialziste o ribassiste. Tuttavia, fornisce aggiornamenti sulla detenzione interna e conferma il proseguimento del servizio della CFO, la cui posizione azionaria e RSU resta allineata agli interessi degli azionisti.

Cardlytics, Inc. (CDLX) – Presentación Formulario 4 de insider para la CFO Alexis DeSieno

La presentación revela una actividad rutinaria con acciones relacionada con unidades de acciones restringidas (RSU) previamente otorgadas. El 1 de julio de 2025, 14,349 RSU se consolidaron y se convirtieron en un número igual de acciones comunes (código de transacción “M”). Inmediatamente después de la consolidación, la CFO poseía beneficiosamente 179,182 acciones comunes.

El 2 de julio de 2025, la CFO realizó una venta de 7,324 acciones (código de transacción “S”) a un precio promedio ponderado de $1.7826 para cubrir obligaciones fiscales asociadas con la entrega de las RSU. Tras la venta, la propiedad directa es de 171,858 acciones comunes.

El premio RSU originalmente cubría 114,796 acciones y se consolida en ocho cuotas trimestrales iguales desde el 1 de julio de 2024 hasta el 1 de abril de 2026, condicionado a la continuidad laboral. Tras las transacciones reportadas, quedan 43,049 RSU pendientes y no ejercidas.

  • No hubo compras en mercado abierto ni ventas discrecionales más allá de la disposición por retención fiscal.
  • Las transacciones no alteran el estatus ejecutivo de la CFO; son operaciones estándar según la Sección 16.

Implicaciones para inversores: La actividad parece administrativa y relacionada con impuestos, sin señales alcistas ni bajistas. Sin embargo, ofrece visibilidad actualizada sobre las participaciones internas y confirma la continuidad en el cargo de la CFO, cuya posición restante en acciones y RSU sigue alineada con los intereses de los accionistas.

Cardlytics, Inc. (CDLX) – CFO Alexis DeSieno의 내부자 보고서 Form 4 제출

이 보고서는 이전에 부여된 제한 주식 단위(RSU)에 관련된 일상적인 주식 활동을 공개합니다. 2025년 7월 1일에 14,349 RSU가 성숙되어 동일한 수의 보통주로 전환되었습니다(거래 코드 “M”). 성숙 직후 CFO는 179,182 주의 보통주를 실질적으로 보유하고 있었습니다.

2025년 7월 2일, CFO는 RSU 지급과 관련된 세금 원천징수 의무를 충당하기 위해 7,324주를 판매하였으며(거래 코드 “S”), 가중평균 가격은 $1.7826였습니다. 판매 후 직접 보유 주식은 171,858주입니다.

RSU 수여는 원래 114,796주에 해당하며 2024년 7월 1일부터 2026년 4월 1일까지 8개의 동일한 분기별 할부로 성숙되며, 계속 고용 조건에 따릅니다. 보고된 거래 이후 43,049 RSU가 아직 미성숙 및 미행사 상태입니다.

  • 원천징수 관련 처분 외에 공개 시장에서의 매수나 임의 매도는 없었습니다.
  • 이 거래들은 CFO의 임원 지위를 변경하지 않으며, 표준 섹션 16 보고 사항입니다.

투자자에 대한 시사점: 이번 활동은 행정적이고 세금 관련된 것으로 보이며, 강세나 약세 의도를 나타내지 않습니다. 다만 내부자 보유 현황을 업데이트하고 CFO의 계속 근무를 확인하며, 남은 주식 및 RSU 보유가 주주 이익과의 정렬을 유지함을 보여줍니다.

Cardlytics, Inc. (CDLX) – Déclaration Formulaire 4 d’initié pour la CFO Alexis DeSieno

La déclaration révèle une activité courante liée à des unités d’actions restreintes (RSU) précédemment attribuées. Le 1er juillet 2025, 14 349 RSU ont été acquises et converties en un nombre égal d’actions ordinaires (code transaction « M »). Immédiatement après l’acquisition, la CFO détenait bénévolement 179 182 actions ordinaires.

Le 2 juillet 2025, la CFO a procédé à une vente de 7 324 actions (code transaction « S ») à un prix moyen pondéré de 1,7826 $ pour couvrir les obligations fiscales liées à la remise des RSU. Après la vente, la détention directe s’élève à 171 858 actions ordinaires.

La dotation initiale en RSU couvrait 114 796 actions et s’acquiert en huit versements trimestriels égaux du 1er juillet 2024 au 1er avril 2026, sous condition de maintien en emploi. Après les transactions rapportées, 43 049 RSU restent en suspens et non exercées.

  • Aucun achat en marché ouvert ni vente discrétionnaire n’a eu lieu en dehors de la disposition liée à la retenue fiscale.
  • Ces transactions ne modifient pas le statut exécutif de la CFO ; ce sont des opérations standard au titre de la Section 16.

Implications pour les investisseurs : L’activité semble administrative et liée à la fiscalité, sans intention haussière ni baissière. Néanmoins, elle offre une visibilité actualisée sur les participations des initiés et confirme la poursuite du mandat de la CFO, dont la position en actions et RSU reste alignée avec les intérêts des actionnaires.

Cardlytics, Inc. (CDLX) – Form 4 Insider-Meldung für CFO Alexis DeSieno

Die Meldung offenbart routinemäßige Aktienaktivitäten im Zusammenhang mit zuvor gewährten Restricted Stock Units (RSUs). Am 1. Juli 2025 sind 14.349 RSUs fällig geworden und wurden in die gleiche Anzahl Stammaktien umgewandelt (Transaktionscode „M“). Unmittelbar nach der Fälligkeit besaß die CFO 179.182 Stammaktien wirtschaftlich.

Am 2. Juli 2025 veräußerte die CFO 7.324 Aktien (Transaktionscode „S“) zu einem gewichteten Durchschnittspreis von 1,7826 $, um Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Auszahlung zu erfüllen. Nach dem Verkauf beträgt das direkte Eigentum 171.858 Stammaktien.

Die RSU-Zuteilung umfasste ursprünglich 114.796 Aktien und wird in acht gleichen vierteljährlichen Raten vom 1. Juli 2024 bis zum 1. April 2026 fällig, vorbehaltlich einer fortgesetzten Anstellung. Nach den gemeldeten Transaktionen sind noch 43.049 RSUs ausstehend und nicht ausgeübt.

  • Es gab keine Käufe am offenen Markt oder diskretionäre Verkäufe über die zweckgebundene Veräußerung hinaus.
  • Die Transaktionen ändern den Status der CFO nicht; es handelt sich um Standardmeldungen gemäß Abschnitt 16.

Implikationen für Investoren: Die Aktivität erscheint administrativ und steuerlich bedingt und signalisiert weder eine bullische noch eine bärische Absicht. Dennoch bietet sie aktualisierte Einblicke in Insider-Beteiligungen und bestätigt die fortgesetzte Tätigkeit der CFO, deren verbleibende Aktien- und RSU-Position im Einklang mit den Interessen der Aktionäre steht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mascolo Elizabeth

(Last) (First) (Middle)
NUMBER ONE GENERAL MILLS BOULEVARD

(Street)
MINNEAPOLIS MN 55426

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENERAL MILLS INC [ GIS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Segment President
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 A 4,585 A $0.0 21,073.287 D
Common Stock 06/30/2025 F 218 D $51.81 20,855.287 D
Common Stock 2,035.9303 I by Trust(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $51.81 06/30/2025 A 22,921 (2) 07/30/2035 Common Stock 22,921 $0.0 22,921 D
Explanation of Responses:
1. Held in Trust by the Trustee of the General Mills Savings Plan.
2. Option vests in four equal annual installments beginning on June 30, 2026.
By: Christopher A. Rauschl For: Elizabeth Mascolo 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Cardlytics CFO Alexis DeSieno sell shares on 2 July 2025?

The 7,324 shares were sold solely to satisfy tax-withholding obligations arising from RSU vesting, according to the filing.

How many Cardlytics shares does the CFO now own?

After the transactions, Alexis DeSieno directly owns 171,858 common shares and holds 43,049 unvested RSUs.

What was the weighted-average sale price in the Form 4?

Shares were sold at a weighted-average price of $1.7826, with individual trades ranging from $1.66 to $1.8451.

Is the insider activity considered bullish or bearish for CDLX?

The transactions appear administrative and tax-related; therefore, analysts generally view them as neutral.

What is the vesting schedule of the CFO’s RSU award?

The original 114,796-share RSU grant vests in eight equal instalments each quarter from 1 July 2024 through 1 April 2026.

Did the Form 4 indicate any change in executive status?

No. Alexis DeSieno continues to serve as Chief Financial Officer of Cardlytics.
General Mills

NYSE:GIS

GIS Rankings

GIS Latest News

GIS Latest SEC Filings

GIS Stock Data

27.32B
540.67M
0.26%
83.92%
4.76%
Packaged Foods
Grain Mill Products
Link
United States
MINNEAPOLIS